Search
Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen
go.drugbank.com/drugs/DB10801ApprovedInvestigationalNeisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria
Proparacaine
go.drugbank.com/drugs/DB00807ApprovedVet approvedProparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
Human Umbilical Cord Mesenchymal Stem Cells
go.drugbank.com/drugs/DB15726InvestigationalThe cells are extracted by either the explant or the enzymatic digestion method, though neither method has been characterized as the ‘standard’ thus far. … resulting in two kinds of MSCs: cord lining mesenchymal stem cells (CLMC), which are used to aid in burn and diabetic ulcer wound healing, and cord lining epithelial stem cells (CLEC), which are used for
KB3305
go.drugbank.com/drugs/DB06349ExperimentalKB3305 is an investigational liver selective antagonist for the glucocorticoid receptor, developed by Karo Bio for the treatment of Type 2 Diabetes.
Alizapride
go.drugbank.com/drugs/DB01425InvestigationalThis kind of pharmacological activity makes it effective for use in the treatment of various kinds of nausea and vomiting, including that which may occur postoperatively.
Categories: Drugs for Functional Gastrointestinal DisordersHydroxyamphetamine
go.drugbank.com/drugs/DB09352ApprovedHydroxyamphetamine is intended mainly as local eye drops for diagnostic purposes. It is indirect sympathomimetic agent which cause dilation of the eye pupil before diagnostic test.
Ligelizumab
go.drugbank.com/drugs/DB11856InvestigationalInitial trials of ligelizumab suggest a greater efficacy over its predecessor for the treatment of CSU.[A242367] … [A242292] Ligelizumab is currently under investigation for the treatment of chronic spontaneous urticaria (CSU), an autoimmune-driven inflammatory condition.
Glycerol phenylbutyrate
go.drugbank.com/drugs/DB08909ApprovedInvestigationalGlycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Xanomeline
go.drugbank.com/drugs/DB15357ApprovedInvestigational[A264514] Xanomeline is a muscarinic agonist that was approved for the treatment of schizophrenia by the FDA in September 2024, becoming the first approved treatment for schizophrenia to target muscarinic
Technetium Tc-99m ciprofloxacin
go.drugbank.com/drugs/DB05488Experimental99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging agent for the potential diagnosis of infection, including fever of unknown origin, osteomyelitis